Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Carnitine in ALS with CHCHD10 Mutations
NCT06849115Phase 4Completed
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of levocarnitine in amyotrophic lateral sclerosis (ALS). Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised at 30 weeks. Started Jul 2024; status: completed.
02
Drugs
levocarnitine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06849115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06849115.